BioTelemetry (NASDAQ: BEAT) reported Q4 EPS of $0.56, $0.13 better than the analyst estimate of $0.43. Revenue for the quarter came in at $103.6 million versus the consensus estimate of $102.84 million.

“2018 was a tremendous year for BioTelemetry. During the year, we fully integrated LifeWatch, achieving all major milestones well ahead of schedule. We also successfully managed the commercial launches of our next generation MCT and extended-wear Holter patch devices as well as our new wireless blood glucose monitor. Furthermore, we forged strategic partnerships with consumer technology and population health management companies seeking to improve the current healthcare delivery system. All of these accomplishments helped us achieve 14% organic revenue growth for the year, deliver significant improvement to our adjusted EBITDA margin and position the Company for continued growth.

“In 2019, we will remain focused on advancing our core strategy, as evidenced by the pending acquisition of Geneva Healthcare. This addition will extend our monitoring expertise into the implantable cardiac device market and further secure our leadership position as the most accurate and comprehensive source of remote cardiac monitoring. We believe the successful execution of our operating plan, coupled with this new service offering, will lead to another record year for the Company.”

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.